Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer

Ítems similars

• Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold!
  per: Fiorelli, Alfonso, et al.
  Publicat: (2020)
• Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer
  per: Shepherd, Annemarie F., et al.
  Publicat: (2020)
• HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer
  per: Yamaoka, Toshimitsu, et al.
  Publicat: (2020)
• Postoperative management for non-small cell lung cancer harboring EGFR mutations
  per: Tanaka, Fumihiro, et al.
  Publicat: (2020)
• Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?
  per: Watanabe, Satomi, et al.
  Publicat: (2016)